Cell Line Development Market Size, Share and Industry Analysis Report by Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope, Electroporators, FACS}, Accessories & Consumables), by Source (Mammalian, Non-

Cell Line Development Market Size, Share and Industry Analysis Report by Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope, Electroporators, FACS}, Accessories & Consumables), by Source (Mammalian, Non-mammalian {Insects, Amphibians}), by Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), by Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2028

The cell line development market is slated to grow considerably by 2028 on account of wide-scale production of vaccines around the world. In addition, the rapidly expanding biotechnology industry is likely to foster market development over the forecast period.

Recent technological innovation in cell line development has propelled market expansion. Moreover, extensive production of COVID-19 vaccines worldwide by leading pharmaceuticals and life sciences corporations has augmented industry uptake during the pandemic.

Furthermore, industry participants have been employing effective strategies to gain a competitive edge in the global market, thereby enhancing business dynamics. For instance, in February 2022, Cytiva, a leading pharmaceutical technology company, inked a partnership agreement with NecstGen, a non-profit contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to scale the development of cell and gene therapies.

The cell line development market has been segmented based on application, product, cell line, source, and region. From the product point of view, the market has further been bifurcated into accessories and consumables, reagents and media, and equipment. In 2021, the accessories and consumables sub-segment held a valuation of around USD 324 million and is foreseen to expand at a sturdy pace over the review timeline. This growth is attributed to growing R&D activities.

In terms of source, the cell line development market has been categorized into non-mammalian and mammalian. The mammalian sub-segment accounted for a staggering market share of about 72% in 2021 and is speculated to develop at a considerable growth rate through the projected period. Widespread production of monoclonal antibodies for targeted therapies is likely to accelerate segmental expansion.

From the cell line perspective, the market has been differentiated into primary cell lines, recombinant, continuous cell lines, and hybridomas. In 2021, the cell line development market size from the continuous cell lines sub-segment was valued at nearly USD 1.2 billion and is expected to witness optimistic progress over the analysis timeline. Prevalent adoption of continuous cell lines owing to their high effectiveness and low nutritional requirements is slated to bolster segmental growth over the following years.

With respect to application, the cell line development market has been segregated into research, bioproduction, tissue engineering, drug discovery, and toxicity testing. The toxicity testing sub-segment garnered approximately 21% market share in 2021 and is anticipated to reach a substantial revenue by the end of 2028 driven by the rise in drug development activities.

On the regional front, the Latin America cell line development industry is poised to expand at a CAGR of more than 10.2% through the study timeframe. Mounting incidences of cancer in the LATAM region is estimated to foster product outlook in the future.